drugset / Trial / NCT03189615

Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects

NCT03189615

Phase 1 Completed 24 enrolled H. Lundbeck A/S
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the impact of mild to moderate hepatic impairment on the pharmacokinetics of a single oral dose of Lu AF35700

Timeline

Start
2017-05-14
Primary completion
2018-02-28
Completion
2018-04-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Lu AF35700 Unknown 10 mg Oral

Indications

No indication recorded.